skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 197,205  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
447 Stage one endometrial cancer. Concept extensions of risk group
447 Stage one endometrial cancer. Concept extensions of risk group
Material Type:
Article 		Add to My Research

447 Stage one endometrial cancer. Concept extensions of risk group

International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A185-A185 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2020-IGCS.388

Full text available

Citations Cited by
2
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Material Type:
Article 		Add to My Research

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

The lancet oncology, 2020-04, Vol.21 (4), p.519-530 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30863-0 ;PMID: 32171426

Full text available

Citations Cited by
3
S2520 Severe Nausea and Hyperemesis Are Not Always Gastrointestinal: Non-GI Immune-Related Adverse Events Presenting as Upper GI Symptoms
S2520 Severe Nausea and Hyperemesis Are Not Always Gastrointestinal: Non-GI Immune-Related Adverse Events Presenting as Upper GI Symptoms
Material Type:
Article 		Add to My Research

S2520 Severe Nausea and Hyperemesis Are Not Always Gastrointestinal: Non-GI Immune-Related Adverse Events Presenting as Upper GI Symptoms

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e1677-e1677 [Peer Reviewed Journal]

2022 by The American College of Gastroenterology ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/01.ajg.0000866720.12455.ce

Full text available

Citations Cited by
4
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Material Type:
Article 		Add to My Research

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

The lancet oncology, 2019-04, Vol.20 (4), p.518-530 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30904-5 ;PMID: 30857956

Full text available

Citations Cited by
5
1036 Comparison of gemcitaibne or liposomal doxorubicin in patients with high grade serous ovarian cancer with partial platinum response
1036 Comparison of gemcitaibne or liposomal doxorubicin in patients with high grade serous ovarian cancer with partial platinum response
Material Type:
Conference Proceeding 		Add to My Research

1036 Comparison of gemcitaibne or liposomal doxorubicin in patients with high grade serous ovarian cancer with partial platinum response

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A331-A332 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.695

Full text available

Citations Cited by
6
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Material Type:
Article 		Add to My Research

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

The lancet oncology, 2019-06, Vol.20 (6), p.816-826 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30097-X ;PMID: 31047803

Full text available

Citations Cited by
7
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Material Type:
Article 		Add to My Research

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2202809

Full text available

Citations Cited by
8
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Material Type:
Article 		Add to My Research

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

The lancet oncology, 2020-11, Vol.21 (11), p.1413-1422 [Peer Reviewed Journal]

2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30453-8

Full text available

Citations Cited by
9
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Material Type:
Article 		Add to My Research

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-11, Vol.20 (11), p.1506-1517 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30626-6 ;PMID: 31582355

Full text available

Citations Cited by
10
Martha’s rule: parallels with acute oncology
Martha’s rule: parallels with acute oncology
Material Type:
Article 		Add to My Research

Martha’s rule: parallels with acute oncology

BMJ (Online), 2023-11, Vol.383, p.p2599-2599 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2023BMJ ;ISSN: 1756-1833 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.p2599

Full text available

Citations Cited by
11
TIMELINESS OF INITIATION OF FIRST COURSE OF CANCER TREATMENT AT A COMMUNITY HOSPITAL-BASED INFUSION CENTER
TIMELINESS OF INITIATION OF FIRST COURSE OF CANCER TREATMENT AT A COMMUNITY HOSPITAL-BASED INFUSION CENTER
Material Type:
Article 		Add to My Research

TIMELINESS OF INITIATION OF FIRST COURSE OF CANCER TREATMENT AT A COMMUNITY HOSPITAL-BASED INFUSION CENTER

Oncology nursing forum, 2023-03, Vol.50 (2), p.C43-C43 [Peer Reviewed Journal]

Copyright Oncology Nursing Society Mar 2023 ;ISSN: 0190-535X ;EISSN: 1538-0688

Full text available

Citations Cited by
12
Connection, reflection, celebration: The personal impact of the celebratory bell in cancer care
Connection, reflection, celebration: The personal impact of the celebratory bell in cancer care
Material Type:
Conference Proceeding 		Add to My Research

Connection, reflection, celebration: The personal impact of the celebratory bell in cancer care

CANNT Journal, 2023, Vol.33 (1), p.168-169 [Peer Reviewed Journal]

Copyright Canadian Association of Nephrology Nurses and Technologists Winter 2023 ;ISSN: 1498-5136

Full text available

Citations Cited by
13
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Material Type:
Article 		Add to My Research

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Journal of the American College of Cardiology, 2018-04, Vol.71 (16), p.1755-1764 [Peer Reviewed Journal]

2018 American College of Cardiology Foundation ;Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Apr 24, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2018.02.037 ;PMID: 29567210

Full text available

Citations Cited by
14
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Material Type:
Article 		Add to My Research

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

The lancet oncology, 2020-06, Vol.21 (6), p.808-820 [Peer Reviewed Journal]

2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30156-X

Full text available

Citations Cited by
15
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Material Type:
Article 		Add to My Research

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

The lancet oncology, 2020-06, Vol.21 (6), p.786-795 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30140-6 ;PMID: 32386568

Full text available

Citations Cited by
16
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809064 ;PMID: 30280641

Full text available

Citations Cited by
17
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply
Material Type:
Article 		Add to My Research

Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply

The lancet oncology, 2023-06, Vol.24 (6), p.e238-e238 [Peer Reviewed Journal]

2023 Elsevier Ltd ;2023. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(23)00214-0 ;PMID: 37146620

Full text available

Citations Cited by
18
Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles
Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles
Material Type:
Article 		Add to My Research

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Drug delivery, 2021-01, Vol.28 (1), p.1237-1255 [Peer Reviewed Journal]

2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 ;2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s) ;ISSN: 1071-7544 ;EISSN: 1521-0464 ;DOI: 10.1080/10717544.2021.1938757 ;PMID: 34142930

Full text available

Citations Cited by
19
2022-RA-1128-ESGO Has endometrial cancer treatment changed during the last years? A cancer registry data-based approach to monitor expected treatment changes after the release of the corresponding S3 guideline
2022-RA-1128-ESGO Has endometrial cancer treatment changed during the last years? A cancer registry data-based approach to monitor expected treatment changes after the release of the corresponding S3 guideline
Material Type:
Article 		Add to My Research

2022-RA-1128-ESGO Has endometrial cancer treatment changed during the last years? A cancer registry data-based approach to monitor expected treatment changes after the release of the corresponding S3 guideline

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A135-A136 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.292

Full text available

Citations Cited by
20
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Material Type:
Article 		Add to My Research

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

The lancet oncology, 2019-02, Vol.20 (2), p.297-310 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30778-2 ;PMID: 30658932

Full text available

Citations Cited by

Results 1 - 20 of 197,205  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (165,657)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1967  (25)
  2. 1967 To 1981  (216)
  3. 1982 To 1995  (1,213)
  4. 1996 To 2010  (14,413)
  5. After 2010  (181,384)
  6. More options open sub menu

Subject 

  1. Cancer Therapies  (181,902)
  2. Science & Technology  (153,325)
  3. Life Sciences & Biomedicine  (137,245)
  4. Oncology  (80,311)
  5. Chemotherapy  (79,491)
  6. Humans  (77,173)
  7. Tumors  (73,591)
  8. Patients  (67,987)
  9. Cancer  (63,937)
  10. Metastasis  (57,541)
  11. Medical Prognosis  (48,531)
  12. Breast Cancer  (42,189)
  13. Female  (36,250)
  14. Proteins  (35,657)
  15. Apoptosis  (34,764)
  16. Care And Treatment  (34,665)
  17. Radiation Therapy  (34,312)
  18. Health Aspects  (29,138)
  19. Kinases  (28,266)
  20. Gene Expression  (26,842)
  21. More options open sub menu

Language 

  1. English  (196,236)
  2. Japanese  (16,620)
  3. Chinese  (830)
  4. Turkish  (364)
  5. Portuguese  (247)
  6. French  (160)
  7. German  (141)
  8. Norwegian  (128)
  9. Polish  (78)
  10. Spanish  (68)
  11. Russian  (38)
  12. Italian  (31)
  13. Korean  (22)
  14. Dutch  (11)
  15. Ukrainian  (7)
  16. Slovenian  (7)
  17. Afrikaans  (6)
  18. Czech  (4)
  19. Romanian  (4)
  20. Persian  (4)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait